// App-Quantinova.ai

8521 : Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory studyNADIM study-SLCG.

Researchers

Presenter

  • Mariano Provencio-Pulla

Principal Investigators

  • Manuel Cobo

  • Amelia Insa

  • Marinha Costa Rivas

  • Margarita Majem

  • Delvys Rodriguez-Abreu

  • Guillermo Lopez-Vivanco

  • Manuel Domine

  • Elvira Del Barco Morillo

  • Bartomeu Massuti

  • Rosario Garcia Campelo

  • Alexandre Martinez Marti

  • Reyes Bernabe

  • Fernando Franco

  • Maria Jove

  • Ricardo Arrabal

  • Paloma Martin

  • Joaquin Casal

  • Virginia Calvo

Medical Centers

  • Hospital Universitario Puerta de Hierro, Madrid, Spain

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Regional Universitario de Malaga, Malaga, Spain

  • Hospital Clinico Universitario, Valencia, Valencia, Spain

  • Complejo Hospital Universitario de Vigo, Vigo, Spain

  • Hospital De Sant Pau, Barcelona, Spain

  • Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain

  • Department of Medical Oncology, Hospital de Cruces, Barakaldo, Spain

  • Oncology Department and Translational Oncology Division, Fundacion Jimenez Diaz Hospital, Madrid, Spain

  • Complejo Asistencial Universitario de Salamanca, Oncology Department, Head of Department, Salamanca, Spain

  • Albacete University Hospital, Albacete, Spain

  • Medical Oncology Service.University Hospital A Coruna (XXIAC-SERGAS), A Coruna, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Puerta de Hierro Majadahonda University Hospital, Madrid, Spain

  • Medical Oncology Department, Institut Catala dOncologia, lHospitalet de Llobregat, Barcelona, Spain

  • Thoracic Surgery Hospital Universitario Carlos Haya, Malaga, Spain

  • Hospital Clinico Universitario, Malaga, Spain

  • Hospital Universitario Puerta de Hierro, Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Paclitaxel

  • Nivolumab

Outcome

  • Unknown

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03081689

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved